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Purpose: This study provides a proof of concept for real-time 4D dose reconstruction for lung
stereotactic body radiation therapy (SBRT) with multileaf collimator (MLC) tracking and assesses
the impact of tumor tracking on the size of target margins.
Methods: The authors have implemented real-time 4D dose reconstruction by connecting their
tracking and delivery software to an Agility MLC at an Elekta Synergy linac and to their in-house
treatment planning software (TPS). Actual MLC apertures and (simulated) target positions are
reported to the TPS every 40 ms. The dose is calculated in real-time from 4DCT data directly
after each reported aperture by utilization of precalculated dose-influence data based on a Monte
Carlo algorithm. The dose is accumulated onto the peak-exhale (reference) phase using energy-mass
transfer mapping. To investigate the impact of a potentially reducible safety margin, the authors have
created and delivered treatment plans designed for a conventional internal target volume (ITV) +
5 mm, a midventilation approach, and three tracking scenarios for four lung SBRT patients. For
the tracking plans, a moving target volume (MTV) was established by delineating the gross target
volume (GTV) on every 4DCT phase. These were rigidly aligned to the reference phase, resulting in
a unified maximum GTV to which a 1, 3, or 5 mm isotropic margin was added. All scenarios were
planned for 9-beam step-and-shoot IMRT to meet the criteria of RTOG 1021 (3×18 Gy). The GTV
3D center-of-volume shift varied from 6 to 14 mm.
Results: Real-time dose reconstruction at 25 Hz could be realized on a single workstation due to the
highly efficient implementation of dose calculation and dose accumulation. Decreased PTV margins
resulted in inadequate target coverage during untracked deliveries for patients with substantial tumor
motion. MLC tracking could ensure the GTV target dose for these patients. Organ-at-risk (OAR)
doses were consistently reduced by decreased PTV margins. The tracked MTV+1 mm deliveries
resulted in the following OAR dose reductions: lung V20 up to 3.5%, spinal cord D2 up to 0.9 Gy/Fx,
and proximal airways D2 up to 1.4 Gy/Fx.
Conclusions: The authors could show that for patient data at clinical resolution and realistic motion
conditions, the delivered dose could be reconstructed in 4D for the whole lung volume in real-time.
The dose distributions show that reduced margins yield lower doses to healthy tissue, whilst target
dose can be maintained using dynamic MLC tracking. C 2016 Author(s). All article content,
except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license
(http://creativecommons.org/licenses/by/4.0/). [http://dx.doi.org/10.1118/1.4965045]
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1. INTRODUCTION
Randomized controlled trials have shown that dose escalation
in stereotactic body radiation therapy (SBRT) for stage I non-
small cell lung cancer results in high tumor control (>90% for
primal local tumor control).1 A stage I lung tumor typically
moves a few millimeters up to a few centimeters due to respi-
ratory motion.2 Assuring dose coverage of the tumor can be
accomplished by deep-inspiration breath-hold or respiratory
gating strategies,3 at the cost of patient discomfort, longer
treatment times, and requiring the patient’s collaboration. The
motion can also be incorporated into treatment planning, by
constructing a planning target volume (PTV) based on an inter-
nal target volume (ITV). The ITV is defined as the composite
volume of gross target volumes (GTVs), delineated on various
phases of a 4DCT reflecting the breathing cycle.4 Although
this straight-forward approach guarantees target coverage for
the whole breathing cycle (as long as the motion in treat-
ment and imaging sessions coincide), the high-dose volume
is unnecessarily large and potentially toxic to surrounding
normal tissues. A refinement of this approach is the mid-
ventilation (midV)/midposition (midP) approach5,6 which is
based on the average tumor position resulting in smaller target
margins. Especially for hypofractionated treatment regimens,
moving away from the very conservative ITV-based PTV is
expected to reduce toxicity.
Tracking was proposed to manage intrafractional motion
as an alternative to breath-hold and gating techniques.7 It does
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not affect patient comfort and has a minimal impact on treat-
ment delivery time. Tumor tracking solutions for lung SBRT
have been presented and evaluated for the robotic Cyberknife
(Accuray Inc., Sunnyvale, CA, USA)8,9 and the gimbaled Vero
(Brainlab AG, Feldkirchen, Germany) machines.10,11 Both
machines are intentionally designed for tumor tracking by
either allowing for moving the whole beam using a robotic
arm or panning and tilting the beam utilizing gimbals. Alter-
natively, multileaf collimator (MLC) tracking was proposed
as a tracking solution for conventional linacs.7,12 The currently
established method is centroid tracking, which aims at dynam-
ically reshaping the treatment field in the beam’s-eye-view
according to the actual recorded target motion. The method
was recently introduced clinically for prostate13 and lung
SBRT.14 If deformations of the tumor are small, centroid
tracking is expected to compensate for a large part of the
motion. In this work we use an in-house implementation
of MLC centroid tracking12 for lung SBRT. We present an
alternative to the ITV and midV planning approaches, which
decreases the PTV size under the assumption MLC tracking
corrects for rigid target volume shifts.
To assess the impact of MLC tracking on target coverage
and organ-at-risk (OAR) dose, the expected deviation between
the planned and delivered dose must be quantified. Several
methods have been proposed to compute the delivered dose
based on offline dose reconstruction.15–18 Recently, we have
presented an online dose reconstruction solution for assess-
ment of prostate SBRT,19 which calculates and accumulates
dose in real-time based on dose-influence data, while account-
ing for the machine/target motion interplay. Dose-influence
data describe the influence of the fluence distribution on
the patient dose. To make this approach applicable to dose
calculation, the fluence distribution is subdivided into small
rectangular segments, called bixels. Online dose reconstruc-
tion provides real-time quality assurance during treatment and
provides the means to directly validate the performance of
MLC tracking. Moreover, it is a prerequisite for replanning
scenarios in which the treatment plan is changed on the fly
during delivery. For example, drift motion might result in
a gradually changing trade-off between target coverage and
OAR dose which can be compensated for during delivery by
replanning between beams.
Schmidt et al.20 have performed a dosimetric analysis for
lung radiation therapy (33 fractions) utilizing 4D offline dose
reconstruction and use isocenter shifts to model the motion.17
We believe that although this method may be of value for
treatment sites with homogeneous tissue and rigid motion
(e.g., prostate), it is flawed by inaccuracies for large tissue
inhomogeneities and deformations as found in the lung. The
group found small changes to target coverage when motion
was incorporated in the dose calculation model and concluded
the effect of interfractional motion is larger than intrafrac-
tional motion. For hypofractionated treatments such as lung
SBRT, however, intrafractional motion does not simply blur
the delivered dose anymore and hence its accurate mitigation is
of importance. The isocenter shift method from Poulsen et al.17
is not suitable for estimation of OAR dose when target motion
is different from OAR motion (as is the case in the lung).
Moreover, this method is based on 3D image data, although
4D image data are usually available. Glitzner et al.21 have
proposed a 4D dose reconstruction pipeline for kidney based
on online MR imaging and generation of a pseudo 4DCT. They
use deformable vector fields (DVFs) to map dose from each
phase to a reference phase. Their dose calculation algorithm
takes 15 s/MLC aperture and hence cannot be utilized in an
online dose reconstruction scenario.
To facilitate a 4D online dose reconstruction solution for
lung SBRT, we identified the following challenges. To incor-
porate the respiratory motion, dose calculation has to be
based on 4D images. Moreover, dose has to be calculated
for each MLC aperture using a Monte Carlo method due
to considerable tissue inhomogeneities often encountered in
lung. Furthermore, accumulating the dose onto a reference
phase requires deformable image registration (DIR) and a
real-time dose mapping algorithm. We add to our previously
presented online dose reconstruction platform19 by providing
implementations for each of these challenges.
The goal of this work is two-fold. Firstly, we present a
fully implemented method to perform real-time 4D dose
reconstruction and show the runtimes of dose calculation and
accumulation. Secondly, we assess whether safety margins
can potentially be reduced when dynamic MLC tracking is
performed for lung SBRT. We have created treatment plans
with various margins for four patients with stage I tumors
and different motion conditions captured on a 4DCT. We have
delivered the plans with and without MLC tracking on a linac
and have assessed the online reconstructed dose.
2. MATERIALS AND METHODS
2.A. Real-time dose reconstruction platform
The 4D online dose reconstruction components presented
in this manuscript were built on top of the software platform
we have presented in Ref. 19. Figure 1 shows the different
components and data transfers as used for this work.
2.A.1. Motion acquisition and delivery
The tracking and delivery software DynaTrack12 is con-
nected to the research version of an Elekta AB (Stockholm,
Sweden) Synergy linac with Agility MLC through a proprie-
tary real-time network interface. DynaTrack is able to receive
motion acquisition data from a variety of peripheral sys-
tems. Motion acquisition was based on simulated data for this
work.
2.A.2. Dose calculation/accumulation/assessment
DynaTrack is connected to the treatment planning soft-
ware (TPS) DynaPlan22 through a TCP/IP network interface.
DynaPlan receives actual target positions and MLC aper-
tures independently at 25 Hz, and is responsible for dose
accumulation. To calculate the dose for a given MLC aperture,
DynaPlan utilizes the real-time µKonRad23 dose calculation
module, which exploits precalculated dose-influence data.
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F. 1. This component diagram shows how the software modules are interfaced to facilitate online 4D dose reconstruction. The solid arrows represent direct
interfaces, the dashed arrow represents an indirect (i.e., file-based) interface.
These data were generated in φMC, a fast central processing
unit (CPU)-based Monte Carlo dose calculation engine.24
2.A.3. RayStation c++ interface
DynaPlan directly interfaces RayStation 4.6 (research
version, RaySearch Laboratories, Stockholm, Sweden)
through an in-house native ++ application program inter-
face,25 which allows importing patient geometries, treatment
plans, and DVFs. The patient geometry and DVFs are
utilized to accommodate real-time dose accumulation in
DynaPlan and µKonRad. The treatment plans are processed
in DynaTrack.
2.B. Real-time energy-mass transfer
Conventional TPSs utilize direct dose mapping (DDM)
to perform dose accumulation for deformed geometries. A
shortcoming of DDM is that it is based on interpolation of dose
values between grids. Dose mapping by energy-mass transfer
(EMT)26 maps energy and mass contribution separately and is
therefore based on the physical definition of dose. Li et al.27
have analyzed the dosimetric differences between DDM and
EMT for several lung cases and conclude that although mean
PTV dose values are similar, significant dose deviations can
occur for local dose features. Therefore, DDM is deemed
inaccurate for applications in which minimum PTV dose plays
an important role.
For this work we have adapted the EMT pseudocode pro-
vided by Li et al.27 to facilitate real-time dose accumulation.
Although the operational semantics of the algorithm were not
changed, it was highly optimized to benefit from CPU caching,
thread-level (using OpenMP)28 and data-level (using AVX)
parallelization. In line with the analysis of Li et al.,27 a dose
grid resolution of ∼2×2×2 mm3 voxels and CT grid / DVF
resolution with ∼1×1×2 mm3 voxels was used.
2.C. Simulation of motion trajectory
For each patient, a tumor trajectory was generated based
on the respective phase-binned 4DCT. An example trajectory
is shown in Fig. 2. An ellipse was fitted to the superior–inferior
(SI) and anterior–posterior (AP) center-of-volume positions
of all GTVs using a least squares estimator. Based on the
ellipse fit and assuming a respiratory period of 5 s, a 2D
sinusoid motion trajectory was created using 25 Hz sampl-
ing. Left–right (LR) motion was ignored as it was smaller
than 3 mm in all cases. Each trajectory was then used as
input for the motion acquisition module of DynaTrack during
delivery.
DynaTrack was extended to compute the respiratory phase
of each acquired target position in real-time. The phase-
binning algorithm is based on previous work by Lu et al.29
but was modified to allow for online binning. Bins are defined
relative to the automatically detected extremal respiratory
positions (“peaks” and “valleys”) in each respiratory cycle.
During real-time motion acquisition and binning, future data
points are not available after acquiring the current data point
making it impossible to use the current respiratory branch
for binning. Instead the data point is phase shifted by one
respiratory cycle, and binned relative to the last fully acquired
exhalation or inhalation branch. The respiratory period is
calculated from the last 20 s worth of motion data using Fourier
analysis.
F. 2. Motion trajectory for patient 3, based on the center of volume of
individual GTVs.
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2.D. Data dependencies for online calculations
Figure 3 presents the dependencies on precalculated data
in the steps of the dose reconstruction algorithm. The activity
diagram in the online dose reconstruction loop box shows how
dose is accumulated during delivery. The dashed arrows relate
the precomputed data to the online step. For each received
MLC aperture, (1) its dose contribution has to be computed by
converting the aperture to beamlet weights and subsequently
multiplying with the dose-influence data for the respective
beam and phase. (2) The energy from the dose contribution is
then computed using the precomputed high-resolution DVFs
and the electron density of the respective phase. (3) The energy
then needs to be divided by the deformed mass of the respective
phase. (4) Finally, the dose can be accumulated to the previ-
ously delivered dose.
2.E. Moving target volume
Assuming that centroid MLC tracking compensates for
rigid target shifts, we have created treatment plans for a track-
ing scenario using the moving target volume (MTV) approach,
which was utilized in Menten et al.30 Figure 4 schematically
shows how construction of the MTV can be compared to the
construction of the conventional ITV. Both methods rely on
the GTV being delineated on each individual 4DCT phase.
An ITV is then constructed by taking the unified maximum
of all GTVs. For the MTV method, all GTVs are first rigidly
aligned to the reference GTV, based on the center of volume.
The MTV is then constructed by taking the unified maximum
of the shifted GTVs.
2.F. Patient cohort and motion conditions
Table I describes the patient data for the cohort analyzed
in this work. Four patients with different tumor motion prop-
erties were selected, which were previously treated with lung
SBRT in our clinic. All tumors were located peripherally
as defined by RTOG 1021. Figure 5 shows the location of
the GTV in the patient for the reference phase. The GTVs
were manually delineated for each individual 4DCT phase.
The GTV maximum motion per direction (SI, AP, and LR)
was calculated in RayStation based on the center-of-volume
shifts. The minimum (min), maximum (max), and reference
(ref) GTV volumes give indication for the tumor deformation.
The resolution was based on the 4D planning CT with 512
×512 voxels/slice. Dose computation and accumulation were
performed on a downsized grid with 256× 256 voxels/slice
using dose-influence data ranging from 18 to 47 GB/patient.
Dose accumulation was performed for the whole patient
volume between the first and last slice containing lung tis-
sue. Each 4DCT phase was registered to the reference phase
(peak exhale) using RayStation’s hybrid DIR module,31
which utilizes image intensities, lung delineations, and patient
contours. The accuracy of DIR was established by visual
assessment.
2.G. Treatment planning rationale
For each patient, treatment plans were created using
RayStation for five different PTVs. First, the conventional ITV
approach with an isotropic 5 mm margin PTVITV+5 was applied
for reference. Then, MTVs were created for each patient
by RayStation scripting, and subsequently 5, 3 and 1 mm
isotropic margins were applied resulting in three additional
PTVs: PTVMTV+5, PTVMTV+3, and PTVMTV+1. All ITV and
MTV treatment plans were designed on the reference phase.
Finally, a midV plan was generated on the midV phase as
described by Wolthaus et al.5 The PTVmidV for these plans was
generated by expanding the GTV by 4.4–7.6 mm depending
on the intrafractional motion observed in the 4DCT scan.
All plans were designed for step-and-shoot IMRT with nine
equidistant beams according to RTOG 1021 (3-Fx) with a D95
prescription of 18 Gy/Fx. Delivery was performed using 6 MV
beams with flattening filter at a 550 monitor units (MU)/min
dose rate.
The ITV+5 and midV plan were delivered in two modes:
Static ITV+5/midV:Actual target position data are ignored
for both delivery and dose accumulation. For ITV+5, the
dose is calculated based on the dose-influence data for the
reference phase only. For midV, the dose is calculated for the
midV phase, respectively. The accumulated dose represents
the planned dose distribution for PTVITV+5/PTVmidV.
Conventional ITV+5/midV: Actual target position
data are ignored for delivery, but incorporated in dose
F. 3. The bottom box contains an activity diagram representing the steps of the online 4D dose reconstruction loop. The loop is performed for each received
MLC aperture. The individual steps are described in more detail in Sec. 2.D. The top box shows all data which are precomputed for each phase before online
dose reconstruction is performed. The dashed arrows show the relation between the precomputed data and the dose reconstruction steps.
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F. 4. The ITV (green contour) is constructed as the unified maximum of the GTVs (magenta contours) of all ten 4DCT phases. The MTV (cyan contour) is
constructed as the unified maximum of rigidly aligned GTVs, based on their center of volume. The CT images in the center column show the reference phase
(peak-exhale). The MTV is shown for a single phase only and is shifted for all other phases. The ITV is constant for all phases. The 4DCT data correspond to
patient 3.
accumulation: the dose is calculated based on the dose-
influence data for the reported phase and warped onto
the reference phase using EMT. This mode simulates
current clinical practice: substantial motion occurs, but
ITV/midV margins prevent cold-spots in the dose to the
GTV.
To assess target coverage and potential dose reduction
to OARs for the MTV plans compared to the ITV+5/midV
plans, all MTV plans were delivered in tracked
mode:
Tracked MTV: Actual target position data are used for
centroid MLC tracking and incorporated in dose accumula-
tion. The dose is calculated based on the dose-influence data
for the reported phase and warped onto the reference phase
using EMT.
To assess the fidelity of tracking and dose mapping from a
technical point of view, we have also analyzed the MTV plans
in nontracked mode:
Static MTV: Technically the same as static ITV+5/midV.
This represents the planned dose distribution for
PTVMTV+1,3,5.
Untracked MTV: Technically the same as conventional
ITV+5/midV. This mode simulates what happens when mar-
gins are decreased without tracking: it is expected that substan-
tial motion degrades the planned dose distribution.
We have compared the untracked and tracked MTV dose
to the static MTV dose. It is expected that when untracked
delivery leads to inadequate GTV coverage, this can be cor-
rected by tracking.
2.H. Delivery analysis
To assess the dosimetric performance of MLC tracking,
four dose-volume histogram (DVH) points were selected for
analysis and computed for the reconstructed dose on the
reference phase. To assess target coverage, D98 GTVref was
T I. Patient cohort descriptors.
Peak-to-peak motion (mm) GTV volume (cm3)
Patient Tumor location SI AP LR 3D Min Max Ref
Lung
slices
Di j size
(GB)
Resolution CT
grid (mm3)
1 Left upper lobe 5.5 2.2 1.2 6.0 9.7 14.5 9.7 116 18 1.37×1.37×2.00
2 Right lower lobe 13.9 2.6 0.4 14.1 2.7 3.6 3.3 122 21 1.05×1.05×2.00
3 Right upper lobe 7.8 6.6 2.6 10.5 23.6 28.5 25.6 118 47 0.98×0.98×2.00
4 Right lower lobe 5.5 3.0 0.6 6.3 8.4 9.9 8.6 128 40 0.98×0.98×2.00
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F. 5. Volume renderings of the patient geometries, showing: lungs (gray), proximal airways (cyan), spinal cord (green), and GTVref (magenta) for the reference
phase.
computed (Dx being defined as the dose exposed to x% of
a volume). To assess dose spillage to the lung, V20 was evalu-
ated.32V20 was computed for the lung volume, after subtracting
GTVref (Vx being defined as the volume exposed to a dose ≥x
Gy of a volume-of-interest). Moreover, D2 was evaluated for
spinal cord and the proximal airways.
Decreasing PTV margins for a constant PTV dose descrip-
tion may result in a decreasing GTV dose. To provide a fair
analysis of OAR dose reduction, we have normalized the dose
distribution: D98 for the GTV for all MTV plans was scaled to
GTV D98 for the conventionally delivered ITV+5 plan.
To show whether dose calculation and accumulation can be
performed before the next MLC aperture arrives (i.e., within
40 ms), we have measured the respective runtimes. For each
patient, mean, 5%-, and 95%-percentiles (5%-per, 95%-per)
were computed for dose calculation and accumulation sepa-
rately for the MTV+1 plan using tracked delivery. The total
runtime includes dose calculation, dose accumulation, MLC
aperture to beamlet conversion, and logging.
2.I. Hardware/software configuration
For this work, DynaPlan was running on an Intel (Santa
Clara, CA, USA) Xeon E5-2697 v3 2.6 GHz in dual config-
uration with 128 GB main memory. DynaTrack was running
on an Intel Xeon E5-2620 2.0 GHz. Both were compiled using
Microsoft (Redmond, WA, USA) Visual Studio 2010/2012
and ran on the Microsoft Windows 7 operating system. All
high-performance algorithms were developed to run on Intel
Xeon multicore CPU systems.
3. RESULTS
3.A. Runtime analysis
Table II summarizes the runtimes for the full real-time
computation required for each incoming MLC aperture in
DynaPlan. The mean runtime for dose calculation and accu-
mulation ranged from 7.3 to 14.9 ms and 13.1 to 9.1 ms,
respectively. The mean total runtime ranged from 21.3 to
34.5 ms. The 95%-percentile ranged from 25.5 to 41.1 ms.
3.B. Dosimetric impact of intrafractional motion
and MLC tracking
The dosimetric results for GTV D98 are summarized in
Fig. 6. All bars with a black texture represent conventional
deliveries, all gray textures the tracked deliveries. All dose
differences are based on dose per fraction and are computed
on the reference phase.
The first row shows the dose difference for GTV D98 rela-
tive to the static (planned) target dose. For patient 1, all dose
differences were negligible (<0.19 Gy). For patient 2–4 and
all MTV plans, D98 decreased up to 4.5 Gy for the untracked
delivery, but could be restored to an increase of 0.07–0.19 Gy
by MLC tracking. The deviations for the midV plans were
small for all patients: −0.02 to 0.15 Gy.
The second row shows the dose difference from GTV D98
relative to the conventionally delivered ITV+5 plan. For the
MTV+3 and MTV+1 plans tracked delivery resulted in a
D98 decrease of 0.24–1.3 Gy. For the MTV+5 plans, ∆D98
ranged from −0.37 to 0.16 Gy. The deviations between the
conventionally delivered midV and ITV+5 plans were −0.42
and 0.25 Gy.
The dosimetric results on OARs for the tracked deliveries
are summarized in Fig. 7. All dose differences are based on
dose per fraction and are computed on the reference phase.
To obtain V20, the fraction dose was normalized to total
dose. All bars with a black texture refer to nonscaled dose
distributions, all gray textures represent the dose distribu-
tions after scaling GTV D98 to GTV D98 from ITV+5
conventional.
The first row shows the relative differences for lung V20
compared to the ITV+5 plan, conventionally delivered. For
all patients and plans V20 decreased. For tracked MTV+1,
T II. Runtime analysis.
Patient 1 Patient 2 Patient 3 Patient 4
5%-per Mean 95%-per 5%-per Mean 95%-per 5%-per Mean 95%-per 5%-per Mean 95%-per
Dose calculation (ms) 6.8 7.9 11.2 5.3 7.3 11.3 12.5 14.9 18.7 9.5 12.0 15.1
Dose accumulation (ms) 11.1 13.1 15.6 12.5 15.4 18.8 15.8 19.1 23.1 12.2 14.9 18.9
Total (ms) 18.5 21.3 25.5 19.0 23.1 31.8 29.7 34.5 41.1 23.2 27.2 32.9
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F. 6. Dosimetric impact of intrafractional motion and MLC tracking for different plans and delivery modes. The first row indicates target coverage relative to
the respective static (planned) case. The second row shows target coverage relative to the conventional ITV+5 case.
MTV+3, and MTV+5, the decrease ranged from 1.4%–3.5%,
1.0%–2.4%, and 0.2%–1.5% respectively. For the conven-
tional midV plans, the decrease was 0.2%–0.6% for patient
1 and 4, and 1.4%–1.5% for patient 2 and 3.
The second row presents the relative differences for spi-
nal cord D2. For all tracked MTV+1 and MTV+3 plans, D2
decreased compared to the conventionally delivered ITV+5
plan. For tracked MTV+1 the decrease ranged from 0.15 to
F. 7. Dosimetric impact of intrafractional motion and MLC tracking for different plans, both nonscaled and scaled to GTV D98 for the conventionally delivered
ITV+5 plan. The dose differences are compared to the conventional ITV+5 case for lung V20, spinal cord D2, and proximal airways D2.
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0.90 Gy, for tracked MTV+3 from 0.021 to 0.35 Gy. For
tracked MTV+5, ∆D2 for spinal cord ranged from −0.13 to
0.18 Gy. The deviations for the midV plans were −0.14 to
0.25 Gy.
The third row shows the relative differences for proximal
airways D2 compared to the conventionally delivered ITV+5
plan. Similar to the spinal cord D2, for all tracked MTV+1
and MTV+3 plans, D2 decreased. For tracked MTV+1 the
decrease ranged from 0.14 to 1.4 Gy, for tracked MTV+3
from 0.026 to 1.1 Gy. For tracked MTV+5, the decrease in D2
ranged from 0.029 to 0.44 Gy. The deviations for the midV
plans were −0.21 to 0.03 Gy.
4. DISCUSSION
4.A. Technical analysis
We have successfully implemented online 4D dose recon-
struction in our research treatment planning and delivery plat-
form. The tracking solution can be used on a conventional
linac. The tracking and delivery software DynaTrack runs on
a computer in the linac control room, while the workstation
running DynaPlan can be placed anywhere, as long as a low-
latency network connection is available. The algorithms for
dose calculation and accumulation reach a high memory band-
width of 50–70 GB/s on the workstation used in this study.
Although the runtimes are reasonably stable, Windows is not
a real-time operating system. Hence there might always be an
unexpected lag, resulting in individual outlier runtimes for a
few scattered instances. The mean computation time per MLC
aperture ranged from 21.3 to 34.5 ms which was well below
40 ms. Hence, a computation rate of 25 Hz can be maintained.
If latency builds up nonetheless, it can be compensated during
beam-off periods, when no accumulation has to be performed.
For the patient data in this study, the runtimes scale with
the size of the dose-influence data. On computers with less
memory bandwidth or computational power, the number of
slices to calculate and accumulate dose for could be decreased
(e.g., to the target region-of-interest only, instead of the whole
lung volume).
For this work, target position data were simulated in Dy-
naTrack. However, the tracking delivery software supports
various motion acquisition methods, like implanted electro-
magnetic transponders33 and ultrasound transducers.34 Dyna-
Track effectively compensates for the additional latency by
prediction.35 The tumor trajectories in this study were gener-
ated based on 4DCT data by fitting an ellipse. The root mean
square error of the fit error was 0.13–0.51 mm, which is
deemed acceptable as it is substantially smaller than the voxel
size utilized for dose reconstruction.
4.B. Dosimetric analysis
We could show that for all cases in which substantial
motion led to inadequate target coverage for the untracked
MTV plans, tracking could successfully recover the GTV
cold-spots. This effect was largest for patient 2 and 3, with
peak-to-peak motion clearly exceeding the photon penumbra
for lung tissue (assumed to be approximately 6.4 mm).36 GTV
cold-spots were not observed for patient 1, for which the GTV
deformation was largest (49% increase compared to volume
on reference phase). Due to the nature of the MTV approach,
the PTV will be strongly influenced by the largest GTV and is
therefore robust against motion. The GTV motion for patient
2–4 was more rigid and hence could be compensated for by
MLC centroid tracking. This serves as a proof of concept for
lung SBRT MLC tracking.
The assessment of lung V20, spinal cord D2, and proximal
airways D2 shows that decreasing the PTV size decreases OAR
dose, potentially reducing toxicity.32 The dose reductions for
spinal cord and proximal airways should be related to the
RTOG 1021 dose constraints. For the spinal cord maximum
point dose is defined as 7.3 Gy/Fx and the volume exceeding
4.1 Gy/Fx should be <1.2 cm3. The evaluated spinal cord
D2 ranged from 3.1 to 3.9 Gy for the ITV+5 conventional
delivery. For some tracked cases D2 for spinal cord was slightly
higher than for the conventional ITV+5 delivery. These differ-
ences are however ≤0.22 Gy and should be attributed to slight
differences in the treatment plans. For the proximal airways
maximum point dose is defined as 10 Gy/Fx and the volume
exceeding 5 Gy/Fx should be <4 cm3. The evaluated proximal
airways D2 ranged from 0.3 to 5.0 Gy for the ITV+5 conven-
tional delivery. The potential of OAR dose decrease makes
MLC tracking an interesting option, especially considering
that SBRT might become an alternative for surgery37 in the
near future. Decreasing toxicity of lung SBRT while maintain-
ing the high control rate will make the therapy applicable to
younger patients than currently exposed to the hypofraction-
ated regiment.
Decreasing the PTV size while planning with a constant D95
prescription of 18 Gy/Fx results in a decreasing GTV dose.
This is caused by the nonuniform dose profiles. It is unclear
how these results influence local control. However, even when
the MUs of the respective plans are scaled up to achieve
GTV doses similar to the ones resulting from the RTOG 1021
prescription, we could show that OAR dose would still clearly
decrease for most DVH points assessed in this study. Proper
dose description for tracked treatments should include GTV
constraints to benefit from the motion compensation.
For the patient data in this study, we could show that
GTV D98 hardly changes for the midV plans when comparing
the conventionally reconstructed dose to the static (planned)
dose. We have also compared the midV plans to the ITV+5
reference. The dose difference for GTV ∆D98 comparing the
conventionally delivered midV to ITV+5 was ≤0.42 Gy. The
maximum dose deviation between the conventionally deliv-
ered midV and ITV+5 for spinal cord and proximal airways
D2 was small: 0.25 Gy. A clear dose difference, however,
was observed for lung V20: for the two patients with the
largest tumor motion (patient 2 and 3), the midV plans show
a decrease of 1.4%–1.5%.
Peulen et al.38 have shown in a clinical study that the
midV/midP approach in combination with online image-
guidance results in a high local control rate. High-dose vol-
umes were smaller for patients with substantial tumor motion
and hence midV/midP must be considered an improvement
Medical Physics, Vol. 43, No. 11, November 2016
6080 Kamerling et al.: Real-time 4D dose reconstruction 6080
over the conventional ITV approach. Our observation of the
clear reduction in lung V20 for a patient with large tumor
motion illustrates this finding. Not being limited to the motion
parameters assessed by a priori 4D imaging, MLC tracking
is expected to handle substantial baseline drifts better than
midV/midP.
When aiming for decreasing the PTV, it should be noted
that intrafractional motion is not the only reason for applying
PTV margins. Setup errors are expected to be compensated by
MLC tracking, but do influence the accuracy of online dose
reconstruction. They should be minimized by in-room imaging
prior to treatment delivery. Delineation uncertainty is a larger
problem as reducing margins is only acceptable when all tumor
cells are encompassed by the GTV boundary. Optimal margin
strategies for robust MLC tracking plans need to be further
investigated, but are considered out of scope for this study.
4.C. Impact and future work
To our knowledge there is currently no other work pub-
lished on 4D dose reconstruction incorporating intrafractional
motion to assess tracked treatments. Work by other groups
focuses on offline dose reconstruction for lung or abdominal
sites. Glitzner et al.21 also use DVFs to accumulate dose on a
reference phase, however, they adopt DDM instead of EMT. In
contrast to this group, our dose computation and accumulation
algorithms run in ≤40 ms on average and hence are suitable for
use in online dose reconstruction scenarios.
The MTV concept considers motion compensation of rigid
shifts only and should be considered conservative for tumors
with substantial deformation. For example, if the tumor ex-
pands in a single 4DCT phase only, this would propagate to
an increased target volume for all phases. Future work should
assess more sophisticated PTV definitions, robust to the actual
patient motion.
It should be noted that this study is focused on the technical
feasibility aspects while its potential clinical impact still needs
to be analyzed in more detail. However, real-time 4D dose
reconstruction serves as a platform to further develop MLC
tracking. Extending rigid tumor tracking to deformation track-
ing will potentially allow tracked treatment for more advanced
lung tumors.
In this study, treatment planning was performed according
to RTOG 1021 for an ITV/midV approach. Taking into ac-
count small local dose features during planning (like pushing
spinal cord D2) makes sense to comply with RTOG, but not
necessarily for a tracking scenario in which treatment fields
are moved intentionally. The trade-off between tight conformal
target dose and optimal OAR sparing in terms of DVH points
should be assessed.
Sonke et al.39 have shown that although the shape of the tu-
mor trajectory was found to be stable interfractionally, baseline
shifts might invalidate the 4DCT planning dataset. Although
MLC tracking is expected to cope with these shifts (depend-
ing on the motion acquisition method), this might result in a
mismatch with the dose-influence data. Therefore, to apply the
proposed online 4D dose reconstruction method, the validity
of the dose-influence data should be assessed prior to each
fraction. To allow for dose reconstruction on anatomy not
captured on 4DCT, patient models could be utilized.40 Inno-
vations in image-guided radiation therapy technology like the
MR-linac41 may ultimately bring 4D online-imaging and have
the potential to continuously update a patient model, robust
to baseline shifts and other anatomy changes. Extending this
work to volumetric arc therapy (VMAT) is hindered by the
substantial increase in dose-influence data. We are currently
investigating the trade-off between the number of beam angles
and the dosimetric accuracy for online dose reconstruction of
VMAT deliveries. Generating dose-influence data on the fly is
currently too slow and we therefore envision future online 4D
dose calculation directly, based on the patient model geometry
and a real-time Monte Carlo dose calculation.
5. CONCLUSIONS
We have implemented and evaluated a software platform
for 4D online dose reconstruction. We have shown that dose
can be calculated and accumulated in real-time at 25 Hz for
the whole lung volume using a clinical voxel resolution utiliz-
ing precalculated dose-influenced data and DVFs. We could
demonstrate for a limited patient cohort how decreased PTV
margins lead to inadequate target coverage during untracked
delivery for patients with substantial motion. Moreover, we
observed that MLC centroid tracking successfully recovers the
GTV target dose for these patients. OAR doses were consis-
tently reduced by reducing PTV margins.
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